{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:06:57Z","timestamp":1784128017186,"version":"3.55.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pancreatology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.pan.2025.08.017","type":"journal-article","created":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T06:30:22Z","timestamp":1756535422000},"page":"950-958","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in patients with early recurrent pancreatic cancer after adjuvant S-1 treatment: A propensity score-matched analysis"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4098-5217","authenticated-orcid":false,"given":"Naohiro","family":"Okano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Sakamaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7561-5558","authenticated-orcid":false,"given":"Takafumi","family":"Mie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2535-6586","authenticated-orcid":false,"given":"Satoshi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7308-5960","authenticated-orcid":false,"given":"Akiko","family":"Todaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunari","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Kamei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8901-7332","authenticated-orcid":false,"given":"Kumiko","family":"Umemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Azemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7706-0015","authenticated-orcid":false,"given":"Yasuyuki","family":"Kawamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6493-4732","authenticated-orcid":false,"given":"Hiroaki","family":"Yanagimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiro","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Imaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Terashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6560-7503","authenticated-orcid":false,"given":"Chigusa","family":"Morizane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4050-2086","authenticated-orcid":false,"given":"Masafumi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5666-1970","authenticated-orcid":false,"given":"Masato","family":"Ozaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4480-0029","authenticated-orcid":false,"given":"Makoto","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0663-6117","authenticated-orcid":false,"given":"Junji","family":"Furuse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pan.2025.08.017_bib1","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.pan.2025.08.017_bib2","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","article-title":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial","volume":"389","author":"Neoptolemos","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.pan.2025.08.017_bib3","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"Folfirinox or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pan.2025.08.017_bib4","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","article-title":"Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)","volume":"388","author":"Uesaka","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.pan.2025.08.017_bib5","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"Folfirinox versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pan.2025.08.017_bib6","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pan.2025.08.017_bib7","unstructured":"NCCN clinical practice guidelines in oncology (NCCN guidelines\u00ae) pancreatic adenocarcinoma version 2.2024."},{"key":"10.1016\/j.pan.2025.08.017_bib8","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised recist guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.pan.2025.08.017_bib9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.critrevonc.2007.04.004","article-title":"Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapy","volume":"64","author":"Colombo","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.pan.2025.08.017_bib10","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s10120-011-0101-x","article-title":"Combination chemotherapy with S-1 plus cisplatin for gastric cancer that recurs after adjuvant chemotherapy with S-1: multi-institutional retrospective analysis","volume":"15","author":"Shitara","year":"2012","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.pan.2025.08.017_bib11","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1001\/jama.2013.279201","article-title":"Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial","volume":"310","author":"Oettle","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.pan.2025.08.017_bib12","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.pan.2012.07.016","article-title":"Treatment outcome for systemic chemotherapy for recurrent pancreatic cancer after postoperative adjuvant chemotherapy","volume":"12","author":"Taniyama","year":"2012","journal-title":"Pancreatology"},{"key":"10.1016\/j.pan.2025.08.017_bib13","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1056\/NEJMoa072252","article-title":"Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine","volume":"357","author":"Sakuramoto","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pan.2025.08.017_bib14","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s10120-018-0815-0","article-title":"A phase ii trial of capecitabine plus cisplatin (XP) for patients with advanced gastric cancer with early relapse after S-1 adjuvant therapy: XParTS-I trial","volume":"21","author":"Nishikawa","year":"2018","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.pan.2025.08.017_bib15","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.pan.2025.08.017_bib16","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.pan.2025.08.017_bib17","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1001\/jama.2023.4428","article-title":"Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with ras wild-type, left-sided metastatic colorectal cancer: a randomized clinical trial","volume":"329","author":"Watanabe","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.pan.2025.08.017_bib18","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00280-016-2972-3","article-title":"Phase I\/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer","volume":"77","author":"Ueno","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.pan.2025.08.017_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.1590","article-title":"GnP vs mFOLFIRINOX or S-IROX in metastatic pancreatic cancer: 1-year follow-up updated data from the GENERATE (JCOG1611)","volume":"35","author":"Kobayashi","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pan.2025.08.017_bib20","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1002\/ijc.34414","article-title":"Chemotherapy in advanced pancreatic adenosquamous carcinoma: a retrospective multicenter AGEO study","volume":"152","author":"Kuentz","year":"2023","journal-title":"Int J Cancer"},{"key":"10.1016\/j.pan.2025.08.017_bib21","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.pan.2022.09.236","article-title":"Efficacy of chemotherapy for patients with metastatic or recurrent pancreatic adenosquamous carcinoma: a multicenter retrospective analysis","volume":"22","author":"Yoshida","year":"2022","journal-title":"Pancreatology"},{"key":"10.1016\/j.pan.2025.08.017_bib22","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1158\/1078-0432.CCR-17-2994","article-title":"Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial","volume":"24","author":"Aung","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pan.2025.08.017_bib23","doi-asserted-by":"crossref","first-page":"5115","DOI":"10.1158\/1078-0432.CCR-22-2576","article-title":"hENT1 expression predicts response to gemcitabine and nab-paclitaxel in advanced pancreatic ductal adenocarcinoma","volume":"28","author":"Perera","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pan.2025.08.017_bib24","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1111\/cas.12501","article-title":"Phase II study of FOLFIRINOX for chemotherapy-naive Japanese patients with metastatic pancreatic cancer","volume":"105","author":"Okusaka","year":"2014","journal-title":"Cancer Sci"},{"key":"10.1016\/j.pan.2025.08.017_bib25","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s00280-018-3577-9","article-title":"A phase II study of modified FOLFIRINOX for chemotherapy-naive patients with metastatic pancreatic cancer","volume":"81","author":"Ozaka","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.pan.2025.08.017_bib26","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1097\/MPA.0000000000001692","article-title":"FOLFIRINOX for recurrent pancreatic cancer after pancreatic resection: a secondary analysis of the nationwide multicenter observational study conducted by the Japan adjuvant study group of pancreatic cancer 06","volume":"49","author":"Morinaga","year":"2020","journal-title":"Pancreas"},{"key":"10.1016\/j.pan.2025.08.017_bib27","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.21873\/anticanres.15145","article-title":"Gemcitabine plus nanoparticle albumin-bound paclitaxel versus FOLFIRINOX for recurrent pancreatic cancer after resection","volume":"41","author":"Taguchi","year":"2021","journal-title":"Anticancer Res"},{"key":"10.1016\/j.pan.2025.08.017_bib28","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1038\/s41416-024-02834-0","article-title":"Clinical utility of BRCA and ATM mutation status in circulating tumour DNA for treatment selection in advanced pancreatic cancer","volume":"131","author":"Sudo","year":"2024","journal-title":"Br J Cancer"},{"key":"10.1016\/j.pan.2025.08.017_bib29","doi-asserted-by":"crossref","first-page":"6204","DOI":"10.1158\/1078-0432.CCR-18-1472","article-title":"Germline and somatic DNA damage repair gene mutations and overall survival in metastatic pancreatic adenocarcinoma patients treated with FOLFIRINOX","volume":"24","author":"Sehdev","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pan.2025.08.017_bib30","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1038\/bjc.2014.418","article-title":"Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers","volume":"111","author":"Golan","year":"2014","journal-title":"Br J Cancer"}],"container-title":["Pancreatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1424390325005915?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1424390325005915?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T14:33:44Z","timestamp":1784126024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1424390325005915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1424390325005915"],"URL":"https:\/\/doi.org\/10.1016\/j.pan.2025.08.017","relation":{},"ISSN":["1424-3903"],"issn-type":[{"value":"1424-3903","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in patients with early recurrent pancreatic cancer after adjuvant S-1 treatment: A propensity score-matched analysis","name":"articletitle","label":"Article Title"},{"value":"Pancreatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pan.2025.08.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 IAP and EPC. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}